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Results: Among the 91 patients included, 67% were
male, mean (SD) age 47.2 (12.9) years, 63 patients with
axSpA and 28 patients with pSpA. The hypothesis de-
fined a priori to test construct validity were confirmed.
The ASAS HI showed ability to discriminate between
patients with different disease activity and functional
states (p<0.001). Internal consistency (Cronbach’s a:
0.88) and test-retest reliability [ICC=0.76 (95%CI
0.09-0.91)] were good. Responsiveness was moderate
(SRM=-0.53). The smallest detectable change was 3.0.
Conclusions: The Portuguese version of the ASAS HI
is a comprehensible questionnaire that is valid, reliable
and responsive. It can be used to assess the impact of
SpA and its treatment on functioning and health, in
clinical practice and for research purposes.
Keywords: Patient reported outcomes; Spondyloarthri-
tis; Patient-reported outcome measure; Quality of life.
INtrODUctION 
Patient reported outcomes (PROs) are outcomes re-
ported directly from patients about how they feel or
function regarding a health condition and its therapy,
irrespective of the influence of their healthcare profes-
sionals or other third parties. These PROs must be re-
ported in a standardized way with the appropriate in-
strument1. Nowadays, there is a growing attention
towards the patient-centered healthcare system2, a phi-
losophy that also influences Rheumatology. In obser-
vational studies, clinical trials, and routine clinical prac-
tice PROs are as important as other measures of efficacy
and safety, since these rely on patient feedback about
health outcomes and as such enhance shared decision-
making, treatment adherence and potentiate better out-
comes3, 4.
The development of PROs in spondyloarthritis (SpA)
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AbstrAct
Objective: The Assessments of SpondyloArthritis in-
ternational Society Health Index (ASAS HI), estimates
the impact of Spondyloarthritis (SpA) on global
functio ning and health. This article assesses the con-
struct validity, reliability and responsiveness of the Por-
tuguese version of the ASAS HI.
Patients And Methods: Patients fulfilling ASAS clas-
sification criteria for axial (axSpA) or peripheral SpA
(pSpA) were included. Construct validity was assessed
through Spearman’s correlation analysis with other
health outcomes. Discriminant validity was tested com-
paring the ASAS HI across disease activity and func-
tional states using the Kruskal–Wallis test. Internal con-
sistency was assessed by Cronbach’s a, and test-retest
reliability by intraclass correlation coefficients (ICC).
Responsiveness was evaluated by the standardized res -
ponse mean (SRM) in patients with active disease who
required therapy escalation.
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has been a longstanding challenge, due to several rea-
sons, such as the heterogeneity and subjectivity of con-
structs to be assessed or the nonspecific nature of in-
flammatory laboratory markers to monitor disease
activity, among other reasons4. From the vast reper-
toire of PROs, the Assessment of SpondyloArthritis in-
ternational Society (ASAS) recommends the use of a
handful in clinical practice, as described elsewhere5.
The ASAS Health Index (ASAS HI) has been recently
developed to measure functioning and health in pa-
tients with SpA with the aim to better define the im-
pact and severity of the disease in these patients6. The
item pool was developed by linking items from exist-
ing questionnaires to the Comprehensive Internation-
al Classification of Functioning, Disability and Health
(ICF) Core Set for Ankylosing Spondylitis (AS). The
category used in the ASAS HI is related to the compo-
nents of body functions, activities and participation6,7.
The ASAS HI is a unidimensional questionnaire,
which includes 17 dichotomous items, addressing pain,
emotional functions, sleep, sexual function, mobility,
self-care and community life representing a wide spec-
trum of different levels of functioning and disability in
patients with SpA8. The sum score of the ASAS HI
ranges from 0 (best health status) to 17 (worse health
status)6. The ASAS HI was originally developed in par-
allel in English speaking countries (Australia, Canada,
Ireland, UK, USA), and it has later been translated and
cross-culturally adapted into 18 languages worldwide,
including European Portuguese9-11. After the review of
the Portuguese version by an expert committee, content
and face validity as well as feasibility (time of comple-
tion) have already been confirmed10, 11. The aim of the
present study was to assess the construct validity, relia -
bility and responsiveness of the European Portuguese
version of ASAS HI. This new questionnaire can be used
to assess, the disease specific, impact of SpA and its
treatment on functioning and health, in clinical practi -
ce and for research purposes.”
PAtIENts AND MEthODs
PAtIENts
A cross-sectional observational study with a longitu-
dinal component for reliability and responsiveness was
performed. SpA patients fulfilling the ASAS classifica-
tion criteria for either axial (axSpA) or peripheral SpA
(pSpA) were included between 2014 and 201712, 13.
The recruitment, taking place in the rheumatology de-
partment of 3 Portuguese hospitals (2 regional, 1 aca-
demic), should include 80% of patients with axial SpA
(40% non-radiographic axSpA (nr-axSpA) and 60%
radiographic axSpA (r-axSpA) and 20% with periph-
eral SpA (pSpA) with no more than 10% of all patients
having concomitant psoriasis. Patients had to be old-
er than 18 years with a range of different disease sever-
ities and all types of treatment. Patients with severe
concomitant diseases that may influence functioning
were excluded as well as patients unable to understand
the objectives of the study and the different question-
naires. The plan was to include at least 25% of the sam-
ple into the “reliability arm” and 25% into the “sensi-
tivity to change arm”. All data were collected by
rheumatologists. All Portuguese patients who partici-
pated in the international validation of the ASAS HI,
were included in the current manuscript. 
EthIcs
This project received approval from the local ethics
committees and written informed consent was ob-
tained from all respondents prior to their participa-
tion, in accordance with the standards of the Helsinki
Declaration of 1975/83.
DAtA cOllEctION
Demographic and clinical information was collected
including age, gender, predominant presentation (i.e.
axial or peripheral), presence of extra-articular mani-
festations (i.e. anterior uveitis, psoriasis, inflammato-
ry bowel disease, other), years of education, employ-
ment status, current medications and C reactive
protein (CRP) levels. Physician’s global assessment of
the patient’s condition was recorded (on numerical 
rating scale (NRS) 0-10 and 4-point Likert scale, very
poor to very good) by answering the questions “How
active was the spondyloarthritis of your patient during
the last week?”, “Please score the overall status of the
subject`s signs and symptoms and the functional ca-
pacity of the subject” and “How do you rate the health
of your patient today?”.
Patients completed a series of self-reported Euro-
pean Portuguese versions of questionnaires at base-
line: ASAS HI6, Bath AS Disease Index (BASDAI)14,
Bath AS Functioning Index (BASFI)14, EuroQol five di-
mensions questionnaire (EQ-5D-5L index and ther-
mometer)15, Short Form Survey Instrument 36-Item
(SF-36)16,17, Hospital Anxiety and Depression Scale
(HAD-S)18, work productivity and activity impairment
questionnaire (WPAI)19, general pain and spinal pain
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HI were considered to be present if more than 15% of
respondents achieved the lowest or highest possible to-
tal score25.
Construct validity was evaluated by Spearman cor-
relation coefficients. Based on the constructs of ASAS
HI and the other PROs, a priori hypotheses were for-
mulated. It was hypothesized that the summary scores
of the ASAS HI would be strongly correlated (0.50 to
0.90) with the BASFI, BASDAI, ASDAS-CRP, and the
SF-36 (physical), and low to moderately correlated
with the HAD-S Anxiety/Depression, SF-36 (mental),
absenteeism and presenteeism (0.3-0.49). The level of
correlation was based on predefined thresholds: low ≤
0.3, moderate 0.3-0.49, good 0.5-0.79 and very good
≥ 0.8, following the international methodology26.
Discriminant validity of the ASAS HI was assessed by
calculating ASAS HI mean scores for predefined
groups, according to: (i) ASDAS disease activity states:
(inactive disease, low, high and very high disease ac-
tivity27; and (ii) BASDAI and BASFI thresholds: <2.0,
2.0–3.99, 4.0–5.99, ≥6.0; using the Kruskal–Wallis
test. In addition, the discriminant validity of the ASAS
HI was assessed by applying the international cutoffs23
defining the three health status groups (Good ≤5.0,
Moderate, <5.0 to <12.0, and Poor ≥12.0). It was hy-
pothesized that participants with higher levels of disea -
se activity or higher functional repercussion would
have higher scores on the ASAS HI than participants
with low levels of disease activity or low functional
repercussion.
Reliability was analyzed by internal consistency and
test-retest reliability. Internal consistency was evalua ted
with the Cronbach’s a coefficient for the total score.
Acceptable internal consistency was defined as a
≥ 0.722. Test–retest reliability was assessed using the in-
traclass correlation coefficient (ICC) for absolute agree-
ment in a two-way ANOVA model. An ICC ≥ 0.80 was
considered to be indicative of excellent reliability28.
Responsiveness was assessed by calculating the stan-
dardized response mean (SRM)26. The magnitude of the
SRM was considered as follows: <0.4 low effect, 
0.4-0.79 moderate effect, and ≥ 0.8 large effect26.
Statistical analysis was performed using Stata ver-
sion 14.0.
rEsUlts
cOhOrt chArActErIstIcs
A total of 91 SpA patients were enrolled in this study,
(on NRS 0–10), and patient global assessment (on NRS
0-10 and 4-point Likert scale, very poor to very good).
Patient’s global assessment about his/her current func-
tioning and health status was recorded by answering
the questions “How do you rate your health today?”,
“Which effect had the disease on your well-being over
the last week?” and “Which effect had the disease on
your well-being over the last six months?”. The Patient
acceptable symptom state (PASS) was recorded with
the question “Considering all the different ways your
disease is affecting you, if you were to stay in this state
for the next few months, do you consider that your cur-
rent state is satisfactory?” (yes/no). The ASDAS score
was calculated as well as ASDAS disease activity
states;20, 21 the EQ-5D index was based on national va -
lue norm15.
For test-retest reliability, patients who considered
themselves in a stable disease state and with stable
treatment (i.e. no change in non-steroidal anti-inflam-
matory drugs (NSAIDs) over the last week, no change
in conventional synthetic disease-modifying an-
tirheumatic drug (csDMARD) or tumor necrosis factor
inhibitor (TNFi) therapy over the last 4 weeks) were in-
vited to complete the same questionnaire at home 4-7
days later. This period of time was considered to be suf-
ficiently short to assume that the variable being mea-
sured had not changed22. Responsiveness was assessed
in a subgroup of patients that required a therapeutic
change (the sensitivity to change arm) with the initia-
tion of an NSAID, csDMARD or TNFi, because of high
disease activity. Patients were reassessed in the clinic
2–24 weeks after the treatment change had been im-
plemented for NSAIDs or 12-24 weeks for csDMARD
or TNFi. Therapeutic changes for reasons other than
clinical disease activity were excluded (i.e. adverse
events, pregnancy wish, patient decision). At the se -
cond assessment, patients were inquired whether their
condition was stable, had improved or had worsened
compared with baseline.
stAtIstIcs
COnsensus-based Standards for the selection of health
Measurement INstruments (COSMIN) recommenda-
tions were followed to test and report measurement
properties23. Psychometric properties were assessed ac-
cording to the Outcome Measures in Rheumatology
(OMERACT) filter24.
Socio-demographic and clinical characteristics were
descriptively analyzed using frequency distributions
and mean values. Ceiling and floor effects of the ASAS
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66% were male, mean (SD) age 47.2 (12.9) years, mean
symptom duration 15 (12) years. There were 63 (69%)
with axSpA (49 (78%) r-axSpA and 14 (22%) 
nr-axSpA) and 28 (31%) pSpA patients. The mean 
ASDAS-CRP was 2.4 (1.1), BASDAI 3.3 (2.3), BASFI
2.6 (2.6) and ASAS HI 6.4 (3.6); 74% of patients were
treated with NSAIDs, 44% with csDMARDs and 18%
with TNFi (Table I). Fourteen patients could not be in-
cluded, neither in the reliability nor in the sensitivity to
change arm, because they did not meet all the require-
ments or due to incomplete data in the second visit.
PsychOMEtrIc PrOPErtIEs Of thE AsAs hI
The average score of the ASAS HI was 6.4 (SD 3.6).
Floor and ceiling effects the ASAS HI of this version
were acceptable (0% and 1.1%, respectively) (Figure 1).
The assessment of the construct validity confirmed
significant correlations, in the expected directions. As
hypothesized, the ASAS HI had a good correlation with
the BASDAI (r=0.77), BASFI (r=0.76), ASDAS-CRP
(r=0.66), and SF-36 PCS (-0.82) and the correlations
were moderate to low with HAD-S Anxiety (r=0.41),
Depression (r=0.45), presenteeism (r=0.44), absen-
teeism (r=0.23). ASAS HI had a good correlation with
SF-36 MCS (-0.62) (Table II). The ASAS HI discrimi-
nated well between patients with different disease 
activity states, measured by ASDAS and BASDAI (both
p<0.01) and function, measured by BASFI (p<0.01)
(Table III). The groups with greater disease activity and
more impaired functioning had higher mean ASAS HI
scores (than those with lower disease activity or lower
functional repercussion). Applying the two cut-off va -
lues as proposed by the international ASAS HI validation
study, (26) we were able to show that the three resulting
groups could discriminate with respect to disease acti -
vity, functioning and health measures (Table IV).
rElIAbIlIty
The ASAS HI scores showed a good internal consis-
tency (Cronbach’s a=0.88). Regarding disease sub-
groups, internal consistency was very good for r-axS-
pA (0.90) and good for nr-axSpA (0.86) but only poor
for pSpA (0.50) 
A total of 70 patients had a second assessment for re-
liability assessment. Test-retest reliability was good with
an overall ICC of 0.76 (95%CI 0.09-0.91) and ICC
were comparable in all disease subtypes (r-axSpA 0.69
(95%CI -0.06 to 0.90); nr-axSpA 0.90 (95%CI 0.66 to
0.97; pSpA 0.79 (95%CI 0.02 to 0.94). The Smallest
Detectable Change was 3.0, which corresponds to the
minimum change beyond measurement error that can
be detected in an individual patient over time26.
rEsPONsIvENEss 
Sensitivity to change was tested in 7 patients consider-
ing themselves to be improved, after therapy intro-
duction. One patient started NSAIDs, 1 patient a csD-
MARD, and 5 patients TNFi. The overall SRM was
moderate (-0.53).
DIscUssION
Current medical practice relies on measurements and
tests. However, at the base of measuring and testing lies
the assumption of uncertainty29. In this context, the pa-
tient perspective gained relevance and contributed to
increase patient adherence and better outcomes.
We have shown that the European Portuguese (PT)
version of the ASAS HI is a valid, reliable and respon-
sive measure to assess functioning and health in PT pa-
tients with SpA. The use of the ASAS HI is feasible since
it contains only 17 items with a yes/no response 
option addressing important and non-redundant 
aspects of patients’ complaints. The calculation to 
obtain a single sum score is simple in order to be fea-
sible for use in clinical practice. In a former analysis we
showed that time of completion was 2.2 ± 0.4 (range
1.2 to 3.2) minutes10. The psychometric properties of
the European PT version of the ASAS HI were consis-
tent with the results found in the international study26,
and also with the validation studies for Colombian-
Spanish30, Italian31 and Korean languages32.
There were no floor and ceiling effects for the ASAS
HI PT total scores, similar to the results obtained in the
international study26. The scores have good content va-
lidity10 and the European PT version of the ASAS HI,
demonstrated excellent correlation with other mea-
sures covering similar constructs of health status (e.g.
activity, functioning, quality of life). As predicted in
terms of construct validity there was a strong correla-
tion with the BASDAI and the physical domain of 
SF-36, meaning that the worse the overall function and
health (higher ASAS HI score) the higher the disease ac-
tivity (higher BASDAI score) and the worse the physi-
cal function (lower SF-36-physical score). In addition,
the good correlation between the ASAS HI and patient
global assessment as well as generic health measures
(such as SF-36) suggests that patients do not make
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tAblE I. sOcIO-DEMOGrAPhIc chArActErIstIcs
All patient Reliability Sensitivity 
Patient characteristics (n=91) (n=70) to change (n=7)
Age (years)     47.2 (12.9) 48.7 (12.7) 43.4 (12.3)
Male, n (%) 60 (66) 43 (61) 6 (86)
Symptom duration (years) 15.1 (12.0) 16.8 (12.1) 14.0 (12.5)
axSpA, n(%) 63 (69) 46 (66) 7 (100)
r-axSpA 49 (78) 36 (78) 6 (86)
Peripheral manifestations, current, n(%)
Arthritis 15 (17) 9 (13) 1 (17)
Dactylitis 0 (0) 0 (0) 0 (0)
Enthesitis 7 (8) 3 (4) 1 (17)
Extra-articular manifestations, current, n(%)
Uveitis 0 (0) 0 (0) 0 (0)
IBD 4 (5) 4 (6) 0 (0)
Skin psoriasis 18 (18) 14 (20) 0 (0)
HLA-B27 positive, n(%) 50 (75) 37 (41) 5 (100) 
CRP (mg/L) 14.2 (16.8) 12.2 (14.7) 22.2 (22.7) 
Elevated CPR (≥0.5mg/L), n(%) 49 (60) 37 (56) 5 (83) 
Current NSAID treatment, n(%) 65 (74) 49 (71) 5 (71)
Current steroids, n(%) 13 (15) 11 (16) 0 (0)
Current csDMARD treatment, n(%) 36 (44) 27 (42) 1 (14)
Current TNFi treatment, n(%) 15 (18) 12 (17) 0 (0)
ASAS HI (0-17) BL 6.4 (3.6) 5.9 (3.5) 9.4 (3.0)
ASAS HI (0-17) T2 4.1 (4.1) 3.8 (4.0) 6.4 (4.7)
ASDAS      2.4 (1.1) 2.2 (0.9) 3.7 (1.0) 
BASDAI (0-10)   3.3 (2.3) 2.9 (2.2) 5.1 (2.0)
BASFI (0-10) 2.6 (2.6) 2.3 (2.5) 4.5 (2.2)
Pain, NRS 0-10 3.7 (2.7) 3.3 (2.6) 6.1 (1.1)
Physician global, NRS 0-10 3.2 (2.1) 3.1 (2.1) 4.5 (2.3)
Patient global, NRS 0-10 3.6 (2.5) 3.1 82.3) 6.0 (1.5)
PASS (yes) 63 (70) 53 (77) 1 (14)
HADS anxiety (0-21) 6.7 (4.2) 6.5 (4.1) 7.0 (2.1)
HADS depression (0-21) 5.5 (3.6) 5.4 (3.3) 7.1 (4.1)
EQ-5D 0.4 (0.5) 0.5 (0.4) 0.2 (0.2)
SF-36 PSC  (0-100) 54.5 (17.8) 56.4 (16.3) 38.3 (13.5)
SF-36 MCS  (0-100) 59.8 (18.2) 62.0 (17.7) 48.6 (14.8)
Employed (yes), n(%) If age ≤ 65 (n=81) 64 (79)  11 (18) 5 (71)
WPAI-SHP if employed
Absenteeism 11.2 (25.6) (n=50) 11.1 (25.2) 6.7 (14.9)
Presenteeism 27.3 (20.6) (n=48) 23.7 (19.7) 44.0 (15.2)
ASAS HI, ASAS Health Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease
Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; csDMARD, conventional synthetic disease-
modifying antirheumatic drug; EQ-5D, Euro Quality of Life 5 Dimensions; HADS, Hospital Anxiety Depression Scale; HLA, human
leucocyte antigen; IBD, inflammatory bowel disease; MSC, mental component summary score; NRS, numerical rating scale; NSAID, non-
steroidal antirheumatic drug; PASS, Patient Acceptable Symptom State; PSC, physical component summary score; SF-36, Short Form 36;
TNFi, tumour necrosis factor inhibitor; VAS, Visual Analogue Scale; WPAI, Work Productivity and Impairment Scale. BL: Baseline; T2,
second time of assessment. Values are presented as mean(SD) or absolute number (%). Percentages are % of available data. Fewer than
5% of the data were missing, except for HLAB27 (26%), physician global (11%) and csDMARD (11%). Unless otherwise stated all
described data is relative to the baseline observation.
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subs tantial distinctions between disease-specific and
more generally worded questionnaires. The adapted
European PT version showed good internal consisten-
cy (Cronbach’s a > 0.88) similar to the Colombian-
Spanish version (Cronbach’s a > 0.91), and a good 
test-retest reliability (ICC > 0.76) similar to the Co lom -
bian-Spanish version (ICC > 0.8)27 but lower than the
Korean (ICC > 0.97)29. Internal consistence was some-
what lower in pSpA vs axSpA patients, maybe due to
the lower sample size and higher chance of outlier 
effect on the pSpA group. In this study the lower ICC
is probably related with the low variance of scores be-
tween participants33.
Importantly, this version of ASAS HI is also applica-
ble in all patients with SpA irrespective of the disease
subgroup. The results in internal consistency were
“very good” in nr-axSpA and “good” in r-axSpA and
pSpA, providing support for the use of these question-
naires in the whole group of patients with SpA. How-
ever, as the ASAS HI was originally developed in a co-
hort of patients with AS/r-axSpA and using AS/r-axSpA
disease-specific questionnaires, caution is advised for
its use in SpA patients other than r-axSpA. This is re-
inforced in the Portuguese population as the number
of pSpA involved was relatively low (n=28, 31%). 
The ASAS HI was sensitive to detect changes after
starting a new pharmacological treatment. The SRM
was moderate (-0.53) similar to the results seen in the
original description of the instrument for NSAIDs
(−0.44) and csDMARDs (−0.69) but lower than for
TNFi (−0.85)26. Considering the low number of pa-
tients involved in the sensitivity to change arm (n=7),
in the Portuguese study the analyses was performed in-
dependently of the therapy (only five of these patients
received TNFi). This may, to some extent, explain the
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fIGUrE 1. Score distribution (0–1 7) of the ASAS Health Index
(ASAS HI) at baseline.
tAblE II. sPEArMAN cOrrElAtION bEtWEEN AsAs hEAlth INDEX scOrEs AND OthEr PrO
Variables Hypothesis R Confirmation
Patient global Good 0.59 Yes
Physician global Moderate 0.39 Yes
BASDAI Good 0.77 Yes
BASFI Good 0.76 Yes
ASDAS-CRP Good 0.66 Yes
SF-36 PCS Good -0.82 Yes
SF-36 MCS Moderate -0.62 No
HAD-S Anxiety Moderate 0.41 Yes
HAD-S Depression Moderate 0.45 Yes
EQ5D Good -0.75 Yes
EQ5D-VAS (0-100) Good 0.21 No
WPAI-SHP 
Absenteeism              Moderate 0.23 No
Presenteeism           Moderate 0.44 Yes
Column indicates whether hypothesis generated prior to analysis about magnitude and direction of correlation was confirmed in the
specific variable. ASAS HI, ASAS Health Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing
Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; EQ-5D, Euro Quality
of Life 5 Dimensions; HADS, Hospital Anxiety Depression Scale; MSC, mental component summary score; PSC, physical component
summary score; SF-36, Short Form 36; WPAI, Work Productivity and Impairment Scale. 
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overall result.
This study has some weaknesses and clear strengths.
In this study test-retest reliability was measured assu -
ming that the disease remains stable in a short period of
time (4-7 days). An additional weakness is related with
the reduced sample size especially in the sensitivi ty to
change arm (n=7). Strengths include the involvement of
patients with different socioeconomic backgrounds, dis-
ease activity, therapies and pSpA subtype, within the
validation process. The total number of patients in-
cluded is higher than in other published versions27,29.
This version of the ASAS HI is validated for the Por-
tuguese population and not for others PT-speaking
populations, for which additional cross-cultural adap-
tation and validation should be performed due to lin-
guistic variations and cultural differences. Another Por-
tuguese version of the ASAS HI is available (Portuguese
from Brazil) and was developed independently during
the international validation project11.
cONclUsION
In conclusion, the PT version of the ASAS HI is a com-
prehensible questionnaire that is valid, reliable and res -
ponsive11. Therefore, it can be used to assess the im-
pact of SpA and its treatment on functioning and
health, in clinical practice and for research purposes.
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tAblE III. DIscrIMINANt vAlIDIty Of AsAs hI (At bAsElINE) strAtIfIED by DIsEAsE ActIvIty AND 
PhysIcAl fUNctIONING
Disease activity p-value
Inactive Low High Very high
ASDAS thresholds (N=16) (N=18) (N=35) (N=22)
ASAS HI 3.3 (1.4) 4.5 (2.0) 6.9 (3.5) 9.4 (3.2) <0.01
BASDAI thresholds <2.0 (n=31) 2.0-3.9 (n=24) 4.0-5.9 (n=21) ≥6.0 (n=13)
ASAS HI 3.8 (1.7) 4.9 (1.9) 8.4 (3.1) 11.5 (2.8)
<0.01
Functioning p-value
BASFI thresholds <2.0 (n=45) 2.0-3.9 (n=19) 4.0-5.9 (n=14) ≥6.0 (n=11)
ASAS HI 4.0 (1.7) 6.6 (2.3) 9.9 (3.4) 11.0 (3.0)
<0.01
All values given as mean (SD), ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease
Index; BASFI: Bath Ankylosing Spondylitis Functioning Index, ASAS HI: ASAS Health Index
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Health state
(number (n), Good Moderate Poor 
% patients) ≤5.0 (n=44,48%) <5.0 to <12.0 (n=37,41%) ≥12.0 (n=10,11%)
ASAS HI 3.5 (1.1) 7.8 (1.6) 13.7 (1.8)
BASFI 0.9 (1.1) 3.6 (2.4) 6.4 (2.0)
BASDAI 1.8 (1.4) 4.1 (1.8) 6.9 (1.8)
ASDAS 1.8 (0.8) 2.7 (0.9) 3.8 (1.1)
SF-36 PCS 67.1 (8.9) 47.4 (13.6) 25.1 (10.8)
EQ-5D 0.7 (0.2) 0.3 (0.3) -0.5 (1.0)
Values given as mean (SD) otherwise indicated. 
ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Index; BASFI: Bath Ankylosing
Spondylitis Functioning Index, ASAS HI: ASAS Health Index; SF36-PSC: Short Form Survey Instrument 36-Item; EQ-5D: EuroQol five
dimensions questionnaire
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